CR20170261A - Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa - Google Patents

Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa

Info

Publication number
CR20170261A
CR20170261A CR20170261A CR20170261A CR20170261A CR 20170261 A CR20170261 A CR 20170261A CR 20170261 A CR20170261 A CR 20170261A CR 20170261 A CR20170261 A CR 20170261A CR 20170261 A CR20170261 A CR 20170261A
Authority
CR
Costa Rica
Prior art keywords
useful
monooxigenasa
inhubers
clorbenzo
quinurenine
Prior art date
Application number
CR20170261A
Other languages
English (en)
Inventor
Ann Louise Walker
Anne Marie Jeanne Bouillot
Alexis Denis
John; Liddle
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1508866.9A external-priority patent/GB201508866D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CR20170261A publication Critical patent/CR20170261A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

El compuesto de fórmula (I) en la que: R1 es heteroarilo no sustituido o sustituido con metilo, etilo, halo o =O; y R2 es H, metilo o etilo; y las sales del mismo son inhibidores de KMO y pueden ser útiles en el tratamiento de diversos trastornos
CR20170261A 2014-12-19 2015-12-17 Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa CR20170261A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422727 2014-12-19
GBGB1508866.9A GB201508866D0 (en) 2015-05-22 2015-05-22 Compounds
PCT/EP2015/080221 WO2016097144A1 (en) 2014-12-19 2015-12-17 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors

Publications (1)

Publication Number Publication Date
CR20170261A true CR20170261A (es) 2017-11-08

Family

ID=54850210

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170261A CR20170261A (es) 2014-12-19 2015-12-17 Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa

Country Status (26)

Country Link
US (2) US9932328B2 (es)
EP (1) EP3233844B1 (es)
JP (1) JP6644790B2 (es)
KR (1) KR102557791B1 (es)
CN (1) CN107108594B (es)
AU (1) AU2015367396C1 (es)
BR (1) BR112017013193B1 (es)
CA (1) CA2969385C (es)
CL (1) CL2017001549A1 (es)
CO (1) CO2017005872A2 (es)
CR (1) CR20170261A (es)
DO (1) DOP2017000141A (es)
EA (1) EA033632B1 (es)
ES (1) ES2737893T3 (es)
IL (1) IL252155B (es)
JO (1) JO3656B1 (es)
MX (1) MX2017008069A (es)
NZ (1) NZ732002A (es)
PE (1) PE20171259A1 (es)
PH (1) PH12017500993A1 (es)
SG (1) SG11201703807VA (es)
TW (1) TWI698433B (es)
UA (1) UA120381C2 (es)
UY (1) UY36451A (es)
WO (1) WO2016097144A1 (es)
ZA (1) ZA201702918B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2969385C (en) * 2014-12-19 2023-03-28 Glaxosmithkline Intellectual Property Development Limited 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
US20100168192A1 (en) * 2007-05-24 2010-07-01 Neurosearch A/S Benzisoxazole derivatives as potassium channel modulators for the treatment of e.g. respiratory diseases, epilepsy and convulsions
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8691824B2 (en) * 2008-08-04 2014-04-08 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2012008346A (es) * 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
US9428464B2 (en) * 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
GB201322512D0 (en) * 2013-12-19 2014-02-05 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2969385C (en) * 2014-12-19 2023-03-28 Glaxosmithkline Intellectual Property Development Limited 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors

Also Published As

Publication number Publication date
ES2737893T3 (es) 2020-01-16
IL252155A0 (en) 2017-07-31
PE20171259A1 (es) 2017-08-28
CA2969385C (en) 2023-03-28
CO2017005872A2 (es) 2017-09-29
BR112017013193B1 (pt) 2023-10-03
EA201791402A1 (ru) 2017-11-30
BR112017013193A2 (pt) 2018-01-02
AU2015367396C1 (en) 2019-05-16
US10273232B2 (en) 2019-04-30
TWI698433B (zh) 2020-07-11
AU2015367396B2 (en) 2018-11-29
TW201629050A (zh) 2016-08-16
JP6644790B2 (ja) 2020-02-12
AU2015367396A1 (en) 2017-05-25
PH12017500993A1 (en) 2017-12-18
UY36451A (es) 2016-07-29
EA033632B1 (ru) 2019-11-12
KR20170095863A (ko) 2017-08-23
NZ732002A (en) 2023-07-28
US20180170921A1 (en) 2018-06-21
KR102557791B1 (ko) 2023-07-19
EP3233844A1 (en) 2017-10-25
WO2016097144A1 (en) 2016-06-23
SG11201703807VA (en) 2017-07-28
CL2017001549A1 (es) 2018-01-26
JO3656B1 (ar) 2020-08-27
MX2017008069A (es) 2017-09-28
ZA201702918B (en) 2019-06-26
DOP2017000141A (es) 2017-07-16
CA2969385A1 (en) 2016-06-23
JP2017537963A (ja) 2017-12-21
CN107108594B (zh) 2020-06-09
IL252155B (en) 2020-11-30
EP3233844B1 (en) 2019-05-15
UA120381C2 (uk) 2019-11-25
US9932328B2 (en) 2018-04-03
US20170349577A1 (en) 2017-12-07
CN107108594A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
CO2017005790A2 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
EA201890641A3 (ru) Стимуляторы sgc
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
EA201690844A1 (ru) Ингибиторы gsk-3
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017003969A2 (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante
BR112016025396A2 (pt) derivados de heterociclil-butanamida
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CR20160073A (es) Compuestos plaguicidas
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CR20160448A (es) Nuevos derivados de piridina
EA201790912A1 (ru) Гетероциклическое соединение
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201900244A1 (ru) Антибактериальные средства на основе производных ципрофлоксацина
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa